Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation

References

• World Health Organization. Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104.
   PubMedGoogle Scholar
• World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. [ cited 2018 August 27]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/
   Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease. CDC Pink Book. 2015;13:279–296.
   Google Scholar
• GAVI Alliance. Countries approved for support: 51 countries approved for pneumococcal vaccine support (PCV). [ cited 2014 June 30]. Available from: http://www.gavialliance.org/results/countries-approved-for-support/
   Google Scholar
• Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013;32:1116–1121.
   PubMed Web of Science ®Google Scholar
• Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007;25:2194–2212.
   PubMed Web of Science ®Google Scholar
• Spijkerman J, van Gils EJ, Veenhoven RH, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011;17:584–591.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.
   PubMed Web of Science ®Google Scholar
• Choi EH, Kim KH, Kim YJ, et al. Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea. Korean J Pediatr. 2011;54:146–151.
   PubMedGoogle Scholar
• Health Protection Agency. Invasive pneumococcal disease incidence rate per 100,000 population by age grouping England and Wales. 1996-2005. [cited 2018 Aug 27]. Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733823380?p=1203409671876
   Google Scholar
• Ho PL, Chiu SS, Cheung CH, et al. Invasive pneumococcal disease burden in Hong Kong children. Pediatr Infect Dis J. 2006;25:454–455.
   PubMed Web of Science ®Google Scholar
• McIntyre P, Gilmour R, Watson M. Differences in the epidemiology of invasive pneumococcal disease, metropolitan NSW, 1997-2001. N S W Public Health Bull. 2003;14:85–89.
   PubMedGoogle Scholar
• Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993;137:977–988.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Chapter 11: pneumococcal - manual for the surveillance of vaccine-preventable diseases. [ cited 2018 August 27]. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html
   Google Scholar
• Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. Lancet Glob Health. 2014;2:e365–366.
   PubMed Web of Science ®Google Scholar
• Silva-Costa C, Brito MJ, Pinho MD, et al. Pediatric complicated pneumonia caused by Streptococcus pneumoniae serotype 3 in 13-valent pneumococcal conjugate vaccinees, Portugal, 2010-2015. Emerg Infect Dis. 2018;24:1307–1314.
   PubMed Web of Science ®Google Scholar
• Cohen O, Knoll M, O’Brien K, et al. Pneumococcal Conjugate Vaccine (PCV) product assessment. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health; 2017.
   Google Scholar
• Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927–936.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187–195.
   PubMed Web of Science ®Google Scholar
• Nurkka A, Ahman H, Korkeila M, et al. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:25–33.
   PubMed Web of Science ®Google Scholar
• Korkeila M, Lehtonen H, Ahman H, et al. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine. 2000;18:1218–1226.
   PubMed Web of Science ®Google Scholar
• Kauppi M, Eskola J, Kayhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J. 1995;14:286–294.
   PubMed Web of Science ®Google Scholar
• Ada G. Vaccines and vaccination. N Engl J Med. 2001;345:1042–1053.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205:1408–1416.
   PubMed Web of Science ®Google Scholar
• Malley R, Trzcinski K, Srivastava A, et al. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A. 2005;102:4848–4853.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Whitney CG, Zell E, et al. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med. 2005;2:e15.
   PubMed Web of Science ®Google Scholar
• Gardner SE, Anderson DC, Webb BJ, et al. Evaluation of Streptococcus pneumoniae type XIV opsonins by phagocytosis-associated chemiluminescence and a bactericidal assay. Infect Immun. 1982;35:800–808.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Hosea SW, Frank MM. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis. 1983;5:S797–805.
   PubMedGoogle Scholar
• Janoff EN, Fasching C, Orenstein JM, et al. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest. 1999;104:1139–1147.
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265–3272.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser. 2005;927:1–154.
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816–3826.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28:S77–88.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66–76.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355–361.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–1348.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14:839–846.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367–376.
   PubMed Web of Science ®Google Scholar
• Millar EV, O’Brien KL, Bronsdon MA, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1173–1179.
   PubMed Web of Science ®Google Scholar
• Dagan R, Juergens C, Trammel J, et al. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. Vaccine. 2016;34:4313–4320.
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952–962.
   PubMed Web of Science ®Google Scholar
• Jokinen JT, Ahman H, Kilpi TM, et al. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004;190:545–550.
   PubMed Web of Science ®Google Scholar
• Pennington SH, Pojar S, Mitsi E, et al. Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage. Am J Respir Crit Care Med. 2016;194:1523–1531.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Trial of pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam (NCT01953510). [ cited 2019 April 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT01953510
   Google Scholar
• Temple B, Toan NT, Uyen DY, et al. Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (the Vietnam Pneumococcal Project): protocol of a randomised controlled trial. BMJ Open. 2018;8:e019795.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Porat N, et al. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. 2012;30:5132–5140.
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Satzke C, et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol. 2010;17:1970–1976.
   PubMed Web of Science ®Google Scholar
• Ota MO, Akinsola A, Townend J, et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine. 2011;29:2999–3007.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Greenberg D. A prospective study to evaluate Streptococcus pneumoniae nasopharyngeal acquisition (SPNA) in the first 30 months of life following a 3-dose primary pneumococcal conjugate vaccine (PCV7) regimen: effect of a booster dose at 12 months of age. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, CA, USA.
   Google Scholar
• Russell FM, Licciardi PV, Balloch A, et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine. 2010;28:3086–3094.
   PubMed Web of Science ®Google Scholar
• Veenhoven RH, Bogaert D, Schilder AG, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis. 2004;39:911–919.
   PubMed Web of Science ®Google Scholar
• Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996;174:1271–1278.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21:27–35.
   PubMedGoogle Scholar
• Fleming-Dutra KE, Conklin L, Loo JD, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33:S152–160.
   PubMed Web of Science ®Google Scholar
• Vesikari T. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage in Finnish children: a cluster-randomized controlled trial. Presented at: ECCMID; 2013 April 27–30; Berlin, Germany.
   Google Scholar
• Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine. 2009;28:71–78.
   PubMed Web of Science ®Google Scholar
• Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J. 2009;28:990–995.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211–1220.
   PubMed Web of Science ®Google Scholar
• van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159–167.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical study result summary for study no. 109563. COMPAS: a phase III study to demonstrate efficacy of GlaxoSmithKline Biologicals’ 10-valent pneumococcal vaccine (GSK1024850A) against community acquired pneumonia and acute otitis media. [ cited 2018 August 27]. Available from: http://www.gsk-clinicalstudyregister.com/files2/22814666-baca-4916-ae7c-dd54f30ae5ba&rct=j&frm=1&q=&esrc=s&sa=U&ved=0CBQQFjAAahUKEwi6oI_C1vvHAhVDrD4KHemvASw&sig2=BvisfYzQchbtNK1ufwvdwA&usg=AFQjCNFZvacPCdwgoww53KJ2perdONAQOQ
   Google Scholar
• Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29:1959–1967.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–1502.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455–1463.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children – a population-based study. PLoS One. 2015;10:e0120290.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33:2684–2689.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471.
   PubMed Web of Science ®Google Scholar
• Kim CH, Kim JS, Cha SH, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 2011;30:e235–243.
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493–505.
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–4203.
   PubMed Web of Science ®Google Scholar
• Togashi T, Okada K, Yamaji M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with DTap vaccine in healthy infants in Japan. Pediatr Infect Dis J. 2015;34:1096–1104.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical study result summary for study 116485. Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants. [ cited 2018 August 27]. Available from: https://www.gsk-clinicalstudyregister.com/files2/116485%20-%20Clinical-Study-Result-Summary.pdf
   Google Scholar
• Wijmenga-Monsuur AJ, van Westen E, Knol MJ, et al. Direct comparison of immunogenicity induced by 10- or 13-valent pneumococcal conjugate vaccine around the 11-month booster in Dutch infants. PLoS One. 2015;10:e0144739.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28:S89–96.
   PubMed Web of Science ®Google Scholar
• van Den Bergh MR, Spijkerman J, Francois N, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 2011;30:e170–178.
   PubMed Web of Science ®Google Scholar
• Temple B, Toan NT, Dai VTT, et al. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. Lancet Infect Dis. 2019;19:497–509.
   PubMed Web of Science ®Google Scholar
• Poolman J, Frasch C, Nurkka A, et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol. 2011;18:327–336.
   PubMed Web of Science ®Google Scholar
• van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, et al. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2015;61:342–349.
   PubMed Web of Science ®Google Scholar
• Cohen R, Varon E, Doit C, et al. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015;33:5118–5126.
   PubMed Web of Science ®Google Scholar
• Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J. 2008;27:335–340.
   PubMed Web of Science ®Google Scholar
• Song JY, Moseley MA, Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19:412–425.
   PubMed Web of Science ®Google Scholar
• Juergens C, Patterson S, Trammel J, et al. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization. Clin Vaccine Immunol. 2014;21:1277–1281.
   PubMed Web of Science ®Google Scholar
• van Den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30–39.
   PubMed Web of Science ®Google Scholar
• Pomat WS, van Den Biggelaar AHJ, Wana S, et al. Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of 10-valent and 13-valent PCV in Papua New Guinean infants. Clin Infect Dis. 2018. [Epub ahead of print]
   Google Scholar
• Isturiz R, Sings HL, Hilton B, et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16:1007–1027.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppa I, et al. Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media-a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5:237–248.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2:e397–405.
   PubMed Web of Science ®Google Scholar
• Andrade AL, Ternes YM, Vieira MA, et al. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One. 2014;9:e98128.
   PubMed Web of Science ®Google Scholar
• Leach AJ, Wigger C, Hare K, et al. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr. 2015;15:162.
   PubMed Web of Science ®Google Scholar
• Lee GM, Kleinman K, Pelton SI, et al. Impact of 13-valent pneumococcal conjugate vaccination on carriage in young children in Massachusetts. J Pediatric Infect Dis Soc. 2014; 3:23–32.
   PubMedGoogle Scholar
• Loughlin AM, Hsu K, Silverio AL, et al. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 2014;33:504–510.
   PubMed Web of Science ®Google Scholar
• Desai AP, Sharma D, Crispell EK, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34:1168–1174.
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Mameli C, Daprai L, et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine. 2014;32:527–534.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297–301.
   PubMed Web of Science ®Google Scholar
• Dunais B, Bruno P, Touboul P, et al. Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France. Pediatr Infect Dis J. 2015;34:286–288.
   PubMed Web of Science ®Google Scholar
• Felix S, Valente C, Tavares D, et al. Temporal trends of serotypes included in the novel 13-valent pneumococcal conjugate vaccine (PCV13) among young children from Portugal. Presented at: ISPPD; 2012 March 11-15; Iguaçu Falls, Brazil.
   Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32:3452–3459.
   PubMed Web of Science ®Google Scholar
• Roca A, Bojang A, Bottomley C, et al. Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia. Vaccine. 2015;33:7144–7151.
   PubMed Web of Science ®Google Scholar
• Van Hoek AJ, Sheppard CL, Andrews NJ, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32:4349–4355.
   PubMed Web of Science ®Google Scholar
• Leach AJ, Wigger C, Beissbarth J, et al. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines. Int J Pediatr Otorhinolaryngol. 2016;86:224–232.
   PubMed Web of Science ®Google Scholar
• Best EJ, Walls T, Souter M, et al. Pneumococcal vaccine impact on otitis media microbiology: a New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine. Vaccine. 2016;34:3840–3847.
   PubMed Web of Science ®Google Scholar
• Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6:23809.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Zanella RC, Almeida SC, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo, Brazil. Vaccine. 2016;34:5604–5611.
   PubMed Web of Science ®Google Scholar
• Galanis I, Lindstrand A, Darenberg J, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47:1208–1218.
   PubMed Web of Science ®Google Scholar
• Collins DA, Hoskins A, Snelling T, et al. Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population. Pneumonia (Nathan). 2017;9:14.
   PubMedGoogle Scholar
• Devine VT, Cleary DW, Jefferies JM, et al. The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine. 2017;35:1293–1298.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Greenberg D, et al. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum Vaccin Immunother. 2016;12:268–276.
   PubMed Web of Science ®Google Scholar
• Dunne EM, Satzke C, Ratu FT, et al. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys. Lancet Glob Health. 2018;6:e1375–e1385.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Erlendsdóttir H, Quirk SJ, et al. Pneumococcal vaccination: direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine. 2017;35:5242–5248.
   PubMed Web of Science ®Google Scholar
• Brandileone M-C, Zanella RC, Almeida SCG, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine. 2016;34:5604–5611.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Akech DO, Morpeth SC, et al. Population impact of 10-valent pneumococcal conjugate vaccine (PCV10) on nasopharyngeal carriage of Streptococcus pneumoniae in Kilifi, Kenya. Presented at: 11th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-11); 2018 April 15-18; Melbourne, Australia.
   Google Scholar
• Bosch AA, van Houten MA, Bruin JP, et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2016;34:531–539.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:258–261.
   Google Scholar
• National Centre for Immunisation Research & Surveillance (NCIRS). Significant events in pneumococcal vaccination practice in Australia. [cited 2019 June 7]. Available from: http://www.ncirs.org.au/sites/default/files/2018-11/Pneumococcal-history-August-2018.pdf
   Google Scholar
• Satzke C, Dunne EM, Choummanivong M, et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine. 2019;37:296–305.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346–1354.
   PubMed Web of Science ®Google Scholar
• Public Health Surveillance. Information for New Zealand Public Health Action. Invasive pneumococcal disease reports. [ cited 2018 August 27]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php
   Google Scholar
• Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–1233.
   PubMed Web of Science ®Google Scholar
• Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207–7211.
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Bonomo RA, et al. Occurrence, distribution, and origins of Streptococcus pneumoniae serotype 6C, a recently recognized serotype. J Clin Microbiol. 2009;47:64–72.
   PubMed Web of Science ®Google Scholar
• Nahm MH, Lin J, Finkelstein JA, et al. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis. 2009;199:320–325.
   PubMed Web of Science ®Google Scholar
• Nunes S, Valente C, Sa-Leao R, et al. Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae. J Clin Microbiol. 2009;47:472–474.
   PubMed Web of Science ®Google Scholar
• Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 2008;198:1818–1822.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables do Neumonias y Meningitis Bacterianas). [ cited 2018 August 27]. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=5536:2011-sireva-ii&Itemid=3966&lang=en
   Google Scholar
• National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. [ cited 2018 August 27]. Available from: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland
   Google Scholar
• Knol MJ, Wagenvoort GH, Sanders EA, et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2015;21:2040–2044.
   PubMed Web of Science ®Google Scholar
• National Institute for Public Health and the Environment. The national immunisation programme in the Netherlands. Surveillance and developments in 2015-2016. [ cited 2018 August 27]. Available from: http://www.rivm.nl/dsresource?objectid=a5cbbe78-1d6e-4263-a214-7fee39b5e287&type=pdf&disposition=inline
   Google Scholar
• Demczuk WH, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013;59:778–788.
   PubMed Web of Science ®Google Scholar
• Wei SH, Chiang CS, Chiu CH, et al. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:e71–77.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–1073.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203–207.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309.
   PubMed Web of Science ®Google Scholar
• Iroh Tam PY, Madoff LC, Coombes B, et al. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134:210–217.
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232–6238.
   PubMed Web of Science ®Google Scholar
• Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61:767–775.
   PubMed Web of Science ®Google Scholar
• Fenoll A, Granizo JJ, Gimenez MJ, et al. Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination. Vaccine. 2015;33:5691–5699.
   PubMed Web of Science ®Google Scholar
• Lefebvre B Programme de surveillance du pneumocoque: rapport 2013. [ cited 2018 August 27]. Available from: https://www.inspq.qc.ca/pdf/publications/1946_Programme_Surveillance_Pneumocoque.pdf
   Google Scholar
• Instituto de Salud Publica de Chile. Boletin Instituto de Salud Publica de Chile. Julio 2015. Vigilancia de laboratorio de Streptococcus pneumoniae procedente de enfermedad invasora. Chile, 2007–2015. [cited 2018 Aug 27]. Available from: http://www.ispch.cl/sites/default/files/Boletín%20de%20Vigilancia%20de%20Laboratorio%20de%20Streptococcus%20pneumoniae.pdf
   Google Scholar
• Instituto de Salud Publica de Chile. Boletin Instituto de Salud Publica de Chile. Junio 2016. Vigilancia de laboratorio de Streptococcus pneumoniae procedente enfermedad invasora. Chile, 2010–2016. [cited 2018 Aug 27]. Available from: http://www.ispch.cl/sites/default/files/BoletinPneumo-27092016C_0.pdf
   Google Scholar
• Australian Government Department of Health. Invasive pneumococcal disease surveillance 2016. [ cited 2016 October 10]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-ipd-reports.htm
   Google Scholar
• Australian Government Department of Health. Pneumococcal disease (invasive) public dataset. [ cited 2016 October 10]. Available from: http://www9.health.gov.au/cda/source/pub_pneum.cfm
   Google Scholar
• Health Protection Surveillance Centre. Annual epidemiological report (Ireland). [ cited 2018 August 27]. Available from: http://www.hpsc.ie/AboutHPSC/AnnualReports/
   Google Scholar
• Regev-Yochay G, Katzir M, Strahilevitz J, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017;35:2449–2456.
   PubMed Web of Science ®Google Scholar
• Knol MJ, De Melker HE, Sanders EAM, et al. Incidence of IPD in the Netherlands up to five years after introduction of PCV10. Presented at: 10th International Symposium on Pneumococci and Pneumococcal Diseases; Glasgow, Scotland, United Kingdom; 2016.
   Google Scholar
• von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371:1889–1899.
   PubMed Web of Science ®Google Scholar
• Richter L, Schmid D, Kanitz EE, et al. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS One. 2019;14:e0210081.
   PubMed Web of Science ®Google Scholar
• Cassiolato AP, Almeida SCG, Andrade AL, et al. Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS One. 2018;13:e0208211.
   PubMed Web of Science ®Google Scholar
• Lu CY, Chiang CS, Chiu CH, et al. Successful control of Streptococcus pneumoniae 19A replacement with a catch-up primary vaccination program in Taiwan. Clin Infect Dis. 2019. [Epub ahead of print]
   Google Scholar
• Pan American Health Organization. SIREVA II regional reports. [ cited 2019 May 15]. Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=5536:2011-sireva-ii&Itemid=3966&lang=en
   Google Scholar
• Leal AL, Montañez AM, Buitrago G, et al. Impact of ten-valent pneumococcal conjugate vaccine introduction on serotype distribution trends in Colombia: an interrupted time-series analysis. Open Forum Infect Dis. 2017;4:S463–S463.
   Google Scholar
• Simell B, Auranen K, Kayhty H, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11:841–855.
   PubMed Web of Science ®Google Scholar
• Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet. 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med. 2006;144:1–9.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122–140.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002;21:1008–1016.
   PubMed Web of Science ®Google Scholar
• Sobanjo-Ter Meulen A, Vesikari T, Malacaman EA, et al. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34:186–194.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Pfizer granted FDA breakthrough therapy designation for 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults aged 18 years and older. [ cited 2019 January 7]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older
   Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycogonjugate vaccines and immune interference: a review. Vaccine. 2010;28:5513–5523.
   PubMed Web of Science ®Google Scholar